Peptides
Anthem offers a range of high-quality peptide APIs designed for various therapeutic applications. These peptides are developed using advanced technology to ensure efficacy, safety, and compliance with global regulatory standards.
Linaclotide
Linaclotide is an oligo-peptide agonist that activates guanylate cyclase 2C receptors on the intestinal epithelium, making it a promising treatment for bowel disorders.
Indications
- Irritable bowel syndrome with constipation (IBS-C).
- Chronic idiopathic constipation (CIC).
- Relief from stomach pain, cramps and bloating.
Mechanism of Action
- Binds to GC-C receptors on the intestinal epithelium.
- Elevates cyclic guanosine monophosphate (cGMP), stimulating chloride and bicarbonate secretion into the intestinal lumen.
- Increases intestinal fluid and accelerates transit for improved bowel movements.
Dosage
- CIC: 72 mcg or 145 mcg orally once daily, at least 30 minutes before the first meal.
- IBS-C: 290 mcg orally once daily, at least 30 minutes before the first meal.
Indications
- Glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
- Reduces the risk of major adverse cardiovascular events in type 2 diabetes patients with established cardiovascular disease.
Mechanism of Action
- Stimulates insulin release in response to elevated glucose levels.
- Decreases glucagon secretion and delays gastric emptying to reduce postprandial glucose spikes.
Dosage
Start at 0.6 mg per day for one week, then increase to 1.2 mg daily; can be further increased to 1.8 mg for additional glycemic control.
Liraglutide
Liraglutide is a GLP-1 receptor agonist that mimics human GLP-1 to regulate blood glucose levels and appetite.
Plecanatide
Plecanatide is a guanylate cyclase-C (GC-C) agonist used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
Indications
CIC and IBS-C in adults.
Mechanism of Action
- Activates GC-C receptors on the gastrointestinal epithelium, increasing cGMP levels.
- Stimulates chloride and bicarbonate secretion into the gastric lumen, enhancing fluid secretion and stool consistency while accelerating intestinal transit.
Dosage
Recommended dose: 3 mg orally once daily.
Indications
Glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Mechanism of Action
- Stimulates insulin secretion while reducing glucagon secretion.
Delays gastric emptying to lower postprandial glucose levels and reduces appetite for calorie control.
Dosage
Start at 0.25 mg weekly; increase to 0.5 mg weekly after four weeks, then up to a maximum of 1 mg weekly if needed.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics human GLP-1 to improve glycemic control and support weight management.
Cilengitide
Cilengitide is a cyclic peptide integrin inhibitor targeting αvβ3 and αvβ5 integrins involved in tumor growth, angiogenesis and cell survival.
Mechanism of Action
Inhibits integrin interaction with extracellular matrix proteins like vitronectin and fibronectin, disrupting tumor signaling pathways.
- Exhibits anti-angiogenic effects by reducing new blood vessel formation required for tumor growth.
- Induces apoptosis in endothelial cells and tumor cells while enhancing chemotherapy and radiation effects by disrupting integrin-mediated repair mechanisms.
Anthem Biosciences ensures its peptide APIs meet stringent quality standards with complete regulatory documentation support for seamless integration into therapeutic applications worldwide.